NASDAQ:MRKR

Marker Therapeutics Q3 2026 Earnings Results & Report

Marker Therapeutics logo
$0.85 +0.02 (+1.98%)
Closing price 04:00 PM Eastern
Extended Trading
$0.85 +0.00 (+0.09%)
As of 07:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Marker Therapeutics beat analyst earnings expectations but missed on revenue in its Q3 2026 results, released November 16, 2026. The company reported EPS of -$0.10 versus the -$0.1167 consensus estimate, while revenue of $1.29 million fell short of the $2.12 million estimate by $822.00 thousand.

Earnings Announcement Details

Quarter
Q3 2026
Time
After Market Closes
Conference Call
7:00 AM ET

Marker Therapeutics EPS Results

Actual EPS
-$0.10
Consensus EPS
-$0.1167
Beat/Miss
Beat by +$0.0167
One Year Ago EPS
N/A
EPS Beat Rate
7 of last 8 quarters

Marker Therapeutics Revenue Results

Actual Revenue
$1.29 million
Expected Revenue
$2.12 million
Beat/Miss
Missed by -$822.00 thousand
YoY Revenue Growth
N/A

Earnings Documents

Marker Therapeutics Q3 2026 Earnings FAQ

Marker Therapeutics (NASDAQ:MRKR) reported earnings of -$0.10 per share for Q3 2026, beating the consensus estimate of -$0.1167. The report was announced on Monday, November 16, 2026.

Marker Therapeutics reported revenue of $1.29 million for Q3 2026, against a consensus estimate of $2.12 million.

Marker Therapeutics Earnings Headlines

What the hell is going on?
Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and the shift is already underway. The dollar has lost 88% of its purchasing power since it was untethered from gold, and Fortune calls the current change the biggest shift in the world's relationship with the dollar in a generation. Stansberry says a similar reset is planned to be unveiled in Miami as soon as this December. Watch Porter Stansberry's full broadcast to see which companies could be affected.tc pixel
See More Marker Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Marker Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Marker Therapeutics and other key companies, straight to your email.

About Marker Therapeutics

Marker Therapeutics is a clinical-stage biotechnology company focused on developing T-cell therapies for cancer. Its platform aims to produce T cells that recognize multiple tumor-associated antigens, with the goal of helping them target cancer cells while reducing the risk that tumors evade treatment by losing a single antigen.

The company’s pipeline includes multi-antigen-specific T-cell candidates for blood cancers. Its programs have included MT-601, studied for lymphoma, and MT-401, developed for acute myeloid leukemia and other hematologic malignancies. These candidates are investigational and remain in clinical development.

Marker Therapeutics was formed in 2018 through a merger involving TapImmune and Marker Therapeutics (NASDAQ:MRKR); TapImmune subsequently adopted the Marker Therapeutics name. The company is based in Houston, Texas, and its development work centers on advancing cell-based cancer treatments.

View Marker Therapeutics Profile